GSK's Promacta wins 'breakthrough' status in severe aplastic anemia
This article was originally published in Scrip
Executive Summary
The US FDA has granted breakthrough therapy designation to GlaxoSmithKline's Promacta (eltrombopag) as a treatment for cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.